However, recent studies have revealed a positive correlation between the expression of CD226 or CD2-CD58 and clinical outcomes across various tumor types in response to cancer treatment, including ICIs and chimeric antigen receptor (CAR) T-cell therapies. Here, CD226 is linked to neoplasm.